Luke Halpern, Assistant Editor

Compared with other treatments for myasthenia gravis, nipocalimab demonstrated more significant improvements in disability scores, with tolerable safety.

The designation builds on previous regulatory action for ADI-001 and allows for expedited development of the treatment for systemic lupus erythematosus.

Donna Ryan discusses the landscape of GLP-1 medications and the lineup of indications that the drug class has received indications for in recent years.

More accurate prognostic risk assessment could aid pharmacists in the management and counseling of patients with primary myelofibrosis.

Often an indicator of fibrosis or damage to the heart, late gadolinium enhancement was found to be unaffected by the administration of intravenous immunoglobulin (IVIG) in pediatric patients with myocarditis.

Higher p16 expression in patients with sickle cell disease led to heightened risk of age-related complications.

Christian Ruff explains the strong efficacy associated with abelacimab compared with rivaroxaban in the AZALEA-TIMI 71 trial.

An inverse relationship was observed between genetic conditions associated with high levels of low-density lipoprotein cholesterol and the risk of developing T2D.

The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.

These results provide a pediatric lens into the potential risk of thromboembolic events in patients with dermatomyositis.

Myelofibrosis patients with CALR mutations have lower responses to symptoms and higher rates of anemia after 6 months of therapy with ruxolitinib.

Donna Ryan, MD discusses GLP-1 medications and new developments on the horizon, while providing some best practices for patients initiating treatment, including important nutritional and lifestyle changes,

Diagnosing anemia, a serious and common complication of patients with myelofibrosis, could be made easier with the use of red cell distribution width assessment.

Data indicates fedratinib’s role as an effective second-line treatment in patients with myelofibrosis who have been previously treated with a JAK inhibitor, such as ruxolitinib, though more research is necessary.

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.

Preliminary phase 1 trial results demonstrate that patients with small cell lung cancer generated early clinical activity after being administered ZL-1310.

The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with these chronic conditions.

The antibody-drug conjugate shows efficacy in reducing disease progression risk and increasing progression-free survival in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer.

Patients with myelofibrosis have a higher likelihood of having a cardiovascular risk factor when compared with essential thrombocythemia or polycythemia vera.

Administered every 4 weeks, the approval could serve as a breakthrough for easier and more effective care for patients with early Alzheimer disease.

Patients recovering from COVID-19 and caregivers reported how some social determinants of health were helpful in their recovery, while others led to difficult social and mental challenges.

Stem cell transplantation rates increased the longer patients remained on therapy for myelofibrosis.

The FDA approved treosulfan, in combination with fludarabine, for patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Engaging with the community, providing transparent information to patients, and using noncoercive methods of encouragement are strategies to reduce COVID-19 vaccine hesitancy.

A series of patient cases demonstrates the potential harm that patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may face when transitioning from intravenous immunoglobulin (IVIG) to FcRn therapy.

Multiple treatments have been approved by regulators for the treatment of hemophilia A and B, giving pharmacists options for their patients.

Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.

These drugs are set to revolutionize their respective disease states in 2025.

Acalabrutinib with bendamustine and rituximab shows efficacy in patients with untreated mantel cell lymphoma by increasing progression-free survival in the ECHO trial.

The finding could help better treat patients with long COVID, as pharmacists and treatment providers can look out for ME/CFS symptoms.